Jun 2026 (Q2 FY26) — Aug 6, 2026
Corvus Q2 FY26 — Socalitinib Pipeline Progress and Atopic Dermatitis Efficacy
Read the full callCorvus (CRVS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Corvus earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -18.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$9.65 +1.37% · +$0.13
Performance +37.1% 1Y
1Y: $7.04 on 17 Oct 2025 → $9.65. High $25.52 (22 Jan 2026), low $6.5 (13 Jan 2026).
- Previous close
- $9.52
- 52-week range
- $6.5 – $25.52
- One year
- +29.18%
Overview
- Symbol
- CRVS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Corvus earnings calls (CRVS)
Financials
What the filings say
Net profit, year on year: −125% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -7 | -8 | -10 | -10 | -11 | -12 | -15 | -19 |
| Other income | -33 | — | 25 | 2 | 0 | — | 1 | — |
| Profit before tax | -40 | -10 | 16 | -8 | -10 | -12 | -13 | -17 |
| Tax rate | — | 0.0% | 0.0% | — | — | — | 0.0% | — |
| Net profit | -40 | -12 | 15 | -8 | -10 | -12 | -14 | -18 |
| EPS ($ per share) | -0.60 | — | 0.21 | -0.10 | -0.12 | — | -0.15 | -0.19 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -170 | -217 | -223 | -266 | -308 | -335 | -397 | -412 |
| Total liabilities | 8 | 13 | 13 | 12 | 12 | 7 | 36 | 10 |
| Fixed assets | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 118 | 84 | 86 | 109 | 68 | 46 | 69 | 71 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41 | -37 | -35 | -37 | -27 | -24 | -25 | -33 |
| Cash from investing | -30 | 3 | 45 | 22 | -23 | 16 | -27 | -8 |
| Cash from financing | 65 | 0 | 1 | 62 | 0 | 8 | 49 | 36 |
| Net cash flow | -6 | -34 | 11 | 47 | -50 | -1 | -4 | -4 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | — | -0 |
| Free cash flow | -41 | -37 | -35 | -37 | -27 | -24 | — | -33 |
Insider filings
16 filings between Jan 28, 2026 and Jun 11, 2026.
Open market
decisions to buy or sellPurchases
$333.7K
3 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 13
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Moore David Scott | $250.2K | — | Jun 11, 2026 |
| MILLER RICHARD A MD | $83.5K | — | May 18, 2026 |
Latest filings (22)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Moore David Scott Director | Purchase | 21,700 | $250.2K |
| May 18, 2026 | MILLER RICHARD A MD President and CEO | Purchase | 5,000 | $60.3K |
| May 18, 2026 | MILLER RICHARD A MD President and CEO | Purchase | 1,932 | $23.2K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 30,000 | $450.0K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $145.5K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $187.5K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $54.1K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $30.0K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $49.0K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $41.1K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $39.0K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $14.8K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $14.5K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $37.4K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $24.6K |
| Jan 28, 2026 | Thompson Peter A. Director | Option exercise | 15,000 | $31.8K |
| Jun 27, 2025 | Thompson Peter A. Director | Option exercised | 1,397,684 | $4.89M |
| Jun 27, 2025 | Thompson Peter A. Director | Sale | 1,176,332 | $4.89M |
| Jun 27, 2025 | ORBIMED ADVISORS LLC Director | Option exercised | 1,397,684 | $4.89M |
| Jun 27, 2025 | ORBIMED ADVISORS LLC Director | Sale | 1,176,332 | $4.89M |
| Jun 4, 2025 | Jones William Benton See Remarks | Option exercise | 19,357 | $67.7K |
| May 7, 2025 | MILLER RICHARD A MD President and CEO | Option exercise | 559,073 | $1.96M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Corvus Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Corvus Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading